A share price of Adc Therapeutics SA [ADCT] is currently trading at $2.22, up 9.36%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ADCT shares have gain 7.77% over the last week, with a monthly amount drifted -27.45%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Adc Therapeutics SA [NYSE: ADCT] stock has seen the most recent analyst activity on November 08, 2024, when Stephens initiated its Overweight rating and assigned the stock a price target of $6. On March 28, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $11 on the stock. JP Morgan upgraded its rating to a Neutral. BofA Securities downgraded its rating to a Underperform and reduced its price target to $2 on April 24, 2023. CapitalOne started tracking with a Overweight rating for this stock on December 06, 2022, and assigned it a price target of $12. In a note dated November 09, 2022, BofA Securities downgraded an Neutral rating on this stock and revised its target price from $14 to $7.
Adc Therapeutics SA experienced fluctuations in its stock price throughout the past year between $0.69 and $6.04. Currently, Wall Street analysts expect the stock to reach $9.33 within the next 12 months. Adc Therapeutics SA [NYSE: ADCT] shares were valued at $2.22 at the most recent close of the market. An investor can expect a potential return of 320.27% based on the average ADCT price forecast.
Analyzing the ADCT fundamentals
Trailing Twelve Months sales for Adc Therapeutics SA [NYSE:ADCT] were 70.72M which represents 27.40% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.97%, Pretax Profit Margin comes in at -2.36%, and Net Profit Margin reading is -3.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.61, Equity is 1.31 and Total Capital is -0.49. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -1.93.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.96 points at the first support level, and at 1.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.43, and for the 2nd resistance point, it is at 2.64.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Adc Therapeutics SA [NYSE:ADCT] is 4.92. Further, the Quick Ratio stands at 4.68, while the Cash Ratio is 4.05. Considering the valuation of this stock, the price to sales ratio is 3.04.
Transactions by insiders
Recent insider trading involved Redmile Group, LLC, 10% Owner, that happened on Jul 01 ’24 when 0.4 million shares were purchased. 10% Owner, Redmile Group, LLC completed a deal on Jul 01 ’24 to buy 0.4 million shares. Meanwhile, Director Azelby Robert sold 6995.0 shares on Jun 17 ’24.
